Almost 12K views now on the zerohedge article. Not
Post# of 1418
(Total Views: 292)
Posted On: 05/09/2022 10:34:20 PM
Almost 12K views now on the zerohedge article. Not as many views as the football game clips, but getting there.
Saw this other article pop up on a bunch of sites in Chinese today. Didn't translate 100% but I like how Pfizer & Todos continue to get mentioned together.
New battlefield against epidemic: Pfizer and others cautiously try to treat long-term symptoms of new crown
Financial Associated Press 2022-05-09 21:52:49
For the long-term symptoms of the new crown, there is currently no officially approved treatment method in the world, and there are very few clinical trials for long-term debilitating symptoms.
Pfizer and Todos Medical have each recently discovered possible solutions, such as 3CL protease inhibitors as a treatment for long-term symptoms of Covid-19. This protease inhibitor reduces viral load and effectively maintains it at low values by preventing viral replication.
This solution could not only help patients, but also help the US economy emerge from its current downturn. It was hard to imagine two years ago that a new virus would have such a huge impact on the global economy.
Statistics show that 15-30% of all people infected with the new crown suffer from long-term illnesses. The outbreak of Omicron last winter had a huge negative impact on people returning to work and maintaining productivity.
Long-term symptoms of Covid-19, also known as Covid-19 sequelae, include general symptoms such as tiredness or fatigue that interferes with daily life, fever, difficulty breathing or shortness of breath, difficulty thinking or concentrating (brain fog), etc . A recent survey by a research team from Japan's Ministry of Health, Labour and Welfare found that about 10 percent of patients in Japan who were hospitalized with symptoms of the new coronavirus infection were still suffering from sequelae a year after discharge.
Long-term symptoms of the new crown are not a small problem
Long-term symptoms of the new crown are no longer a small problem, but a big problem that needs to be solved urgently. It has infiltrated worker productivity issues, exacerbating labor shortages. The Labor Department reported that nonfarm labor productivity fell 7.5% in the most recent quarter, the largest drop since 1947.
The Guardian has previously reported that the new coronavirus may cause physical defects in this generation. Unless a medical solution is found soon, the lack of labor supply could be a permanent threat.
According to Dr. Steven Deeks, a professor of medicine at the University of California, San Francisco, chronic fatigue symptoms in patients with chronic Covid-19 "feel like being hit by a truck."
An autopsy conducted by the National Institutes of Health (NIH) of 44 people who died from the new coronavirus found that the virus infected the whole body, including the brain, and related symptoms could last for more than seven months after they appeared.
The case study of Pfizer and Todos
Right now, it looks like a case study match between Pfizer and Todos, with Pfizer taking the lead with case studies in patients with long-term symptoms, while Todos has been targeting the 3CL protease as an antiviral target.
Pfizer was the first to announce a case study of two patients with chronic symptoms. Both patients had their symptoms gone after taking Pfizer's antiviral drug Paxlovid.
Dr. Michael Peluso provided 3 additional case studies. In its case preprint, 2 long-term patients had significant effects after taking Paxlovid, but one patient experienced relapse. Still, doctors believe there is evidence of the drug's efficacy in treating long-term symptoms , and research needs to be done soon. But Pfizer has no plans to continue clinical trials because the FDA last week did not allow Pfizer to extend its course of treatment with Paxlovid.
The drug developed by Todos, called Tollovid, is a 3CL protease inhibitor, like Paxlovid, but it also has anti-cytokine properties and can be used at almost any stage of the disease.
Interestingly, these patients had previously taken Paxlovid, showing a trend toward remission of long-term symptoms following Tollovid in three published case studies.
Will Paxlovid be toxic if taken for a long time?
The problem with Paxlovid, however, is that its long-term safety as a combination of ritonavir and nirmatrelvir is questionable. The combination is intended to be a short-term antiviral drug to quell acute Covid-19 infections, mainly in critically ill patients.
One of the nitreprevir tablets is designed to inhibit SARS-CoV-2 proteins to stop the virus from replicating, and the other ritonavir tablet slows the breakdown of nitreprevir to help it stay in the body longer at higher concentrations time activity. The problem is that even with this combination therapy, the virus rebounds, causing long-term symptoms.
The main difference between Todos Medical's Tollovid and Pfizer's Paxlovid is that Tollvid is an all-natural supplement, not a chemical drug. "All natural" means unlikely to have any toxicity.
A patient who had taken Paxlovid tweeted that the virus rebounded on the fifth day after taking the drug, "Paxlovid makes me feel weird inside, like poisoned."
A growing body of research suggests that the treatment of long-term symptoms of COVID-19 can be achieved by reducing viral load and keeping it low. A comprehensive case study by Paxlovid and Tollovid suggests that 3CL protease inhibitors may be a treatment for long- term symptoms of COVID-19.
Saw this other article pop up on a bunch of sites in Chinese today. Didn't translate 100% but I like how Pfizer & Todos continue to get mentioned together.
New battlefield against epidemic: Pfizer and others cautiously try to treat long-term symptoms of new crown
Financial Associated Press 2022-05-09 21:52:49
For the long-term symptoms of the new crown, there is currently no officially approved treatment method in the world, and there are very few clinical trials for long-term debilitating symptoms.
Pfizer and Todos Medical have each recently discovered possible solutions, such as 3CL protease inhibitors as a treatment for long-term symptoms of Covid-19. This protease inhibitor reduces viral load and effectively maintains it at low values by preventing viral replication.
This solution could not only help patients, but also help the US economy emerge from its current downturn. It was hard to imagine two years ago that a new virus would have such a huge impact on the global economy.
Statistics show that 15-30% of all people infected with the new crown suffer from long-term illnesses. The outbreak of Omicron last winter had a huge negative impact on people returning to work and maintaining productivity.
Long-term symptoms of Covid-19, also known as Covid-19 sequelae, include general symptoms such as tiredness or fatigue that interferes with daily life, fever, difficulty breathing or shortness of breath, difficulty thinking or concentrating (brain fog), etc . A recent survey by a research team from Japan's Ministry of Health, Labour and Welfare found that about 10 percent of patients in Japan who were hospitalized with symptoms of the new coronavirus infection were still suffering from sequelae a year after discharge.
Long-term symptoms of the new crown are not a small problem
Long-term symptoms of the new crown are no longer a small problem, but a big problem that needs to be solved urgently. It has infiltrated worker productivity issues, exacerbating labor shortages. The Labor Department reported that nonfarm labor productivity fell 7.5% in the most recent quarter, the largest drop since 1947.
The Guardian has previously reported that the new coronavirus may cause physical defects in this generation. Unless a medical solution is found soon, the lack of labor supply could be a permanent threat.
According to Dr. Steven Deeks, a professor of medicine at the University of California, San Francisco, chronic fatigue symptoms in patients with chronic Covid-19 "feel like being hit by a truck."
An autopsy conducted by the National Institutes of Health (NIH) of 44 people who died from the new coronavirus found that the virus infected the whole body, including the brain, and related symptoms could last for more than seven months after they appeared.
The case study of Pfizer and Todos
Right now, it looks like a case study match between Pfizer and Todos, with Pfizer taking the lead with case studies in patients with long-term symptoms, while Todos has been targeting the 3CL protease as an antiviral target.
Pfizer was the first to announce a case study of two patients with chronic symptoms. Both patients had their symptoms gone after taking Pfizer's antiviral drug Paxlovid.
Dr. Michael Peluso provided 3 additional case studies. In its case preprint, 2 long-term patients had significant effects after taking Paxlovid, but one patient experienced relapse. Still, doctors believe there is evidence of the drug's efficacy in treating long-term symptoms , and research needs to be done soon. But Pfizer has no plans to continue clinical trials because the FDA last week did not allow Pfizer to extend its course of treatment with Paxlovid.
The drug developed by Todos, called Tollovid, is a 3CL protease inhibitor, like Paxlovid, but it also has anti-cytokine properties and can be used at almost any stage of the disease.
Interestingly, these patients had previously taken Paxlovid, showing a trend toward remission of long-term symptoms following Tollovid in three published case studies.
Will Paxlovid be toxic if taken for a long time?
The problem with Paxlovid, however, is that its long-term safety as a combination of ritonavir and nirmatrelvir is questionable. The combination is intended to be a short-term antiviral drug to quell acute Covid-19 infections, mainly in critically ill patients.
One of the nitreprevir tablets is designed to inhibit SARS-CoV-2 proteins to stop the virus from replicating, and the other ritonavir tablet slows the breakdown of nitreprevir to help it stay in the body longer at higher concentrations time activity. The problem is that even with this combination therapy, the virus rebounds, causing long-term symptoms.
The main difference between Todos Medical's Tollovid and Pfizer's Paxlovid is that Tollvid is an all-natural supplement, not a chemical drug. "All natural" means unlikely to have any toxicity.
A patient who had taken Paxlovid tweeted that the virus rebounded on the fifth day after taking the drug, "Paxlovid makes me feel weird inside, like poisoned."
A growing body of research suggests that the treatment of long-term symptoms of COVID-19 can be achieved by reducing viral load and keeping it low. A comprehensive case study by Paxlovid and Tollovid suggests that 3CL protease inhibitors may be a treatment for long- term symptoms of COVID-19.
(1)
(0)Todos Med Ltd. (TOMDF) Stock Research Links
Scroll down for more posts ▼